Otsuka Pharmaceuticals was dealt a setback yesterday when the FDA approved four generic versions of its best-selling Abilify antipsychotic pill, following an unusual and protracted legal battle.

May 28 (Reuters) - Otsuka Pharmaceutical Co Ltd has lost a lawsuit challenging the U.S. Food and Drug Administration's decision to allow generic versions of the company's antipsychotic drug Abilify.

Makers of the blockbuster drug Abilify have until September 1 to come up with a way to settle more than 800 lawsuits that claim the anti-psychotic and anti-depressive drug spurred uncontrollable urges ...